Aurinia Pharmaceuticals Strategy and Business Model

Executive Overview

Aurinia is a Canadian-domiciled, commercial-stage biopharmaceutical company focused on autoimmune disease. Its business today is dominated by LUPKYNIS (voclosporin), an oral calcineurin inhibitor approved in the United States for adults with active lupus nephritis, a serious kidney manifestation of systemic lupus erythematosus. Aurinia’s strategy is relatively clear: maximize LUPKYNIS in the U.S. through targeted specialist commercialization, payer-access work, and patient-support infrastructure; capture value outside the U.S. through partners rather than build a full global sales network; and use the cash flow and strategic flexibility created by LUPKYNIS to broaden its autoimmune pipeline. The company is headquartered in Edmonton, Alberta, with major U.S. commercial operations in Maryland, and traces its roots to Isotechnika in the 1990s; the current Aurinia was formed in 2013. In FY2023, Aurinia reported roughly $180 million of revenue. That leaves it in a distinctive middle ground: more mature than a pre-revenue biotech, but still highly concentrated around one marketed product, which makes execution in diagnosis, access, initiation, and persistence unusually important.

Aurinia at a Glance

Logo
Common name	Aurinia
Full legal name	Aurinia Pharmaceuticals Inc.
Headquarters	Edmonton, Alberta, Canada
Ownership	Public company; institutionally owned; no controlling shareholder publicly disclosed as of 2024
Ticker	AUPH
Exchange	NASDAQ
Market Cap	$2.31B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Roots in Isotechnika (1993); current Aurinia formed in 2013; FDA approval of LUPKYNIS in 2021
Industry or industries	Biopharmaceuticals; specialty pharmaceuticals; autoimmune disease therapeutics
Key products or services	LUPKYNIS for active lupus nephritis; ex-U.S. licensing and collaboration arrangements; autoimmune pipeline development
Geographic footprint	U.S.-focused commercialization with partnered rights in Europe, Japan, and certain other territories; corporate presence in Canada and the United States
Business segments as officially reported	One reportable segment
Company website	https://www.auriniapharma.com

1. What Is the Strategy of Aurinia?

Using the Playing to Win framework, Aurinia’s public disclosures point to a focused specialty-biopharma strategy rather than a broad-platform model.

1. 1a. What is the winning aspiration of Aurinia?

   Aurinia’s stated purpose centers on improving outcomes for patients with autoimmune disease, with lupus nephritis as the company’s first and most developed commercial beachhead. In practical terms, “winning” appears to mean three things: making LUPKYNIS a standard part of treatment for appropriate adult patients with active lupus nephritis in the U.S.; extracting value from territories outside the U.S. through partnerships; and reducing long-term dependence on a single asset by building a broader autoimmune pipeline.

   As of 2024, Aurinia had not made a single long-range public financial target the centerpiece of its filings. The company’s communications are more operational: growth in patient starts, broader specialist adoption, durable persistence, and expansion of the pipeline beyond voclosporin.

2. 1b. Where does Aurinia play?

   Aurinia plays in a narrow but high-need part of immunology: autoimmune disease with a current commercial focus on adult active lupus nephritis. The company’s direct commercial effort is concentrated in the United States, where it sells LUPKYNIS through a targeted specialty model aimed primarily at nephrologists and rheumatologists who diagnose and co-manage lupus nephritis.

   Outside the U.S., Aurinia has chosen to play more selectively, using partners rather than constructing a full in-house commercial footprint. Strategically, its pipeline ambitions suggest it wants to remain in autoimmune and inflammation-linked diseases where its renal and immunology experience is transferable, rather than diversify into unrelated therapeutic areas.

3. 1c. How does Aurinia plan to win?

   Aurinia’s core “how to win” is differentiation within a concentrated market. LUPKYNIS gives the company a distinct offering: an oral branded therapy for lupus nephritis supported by clinical data and aimed at improving renal response when used with background therapy. That matters because lupus nephritis has historically been treated with a mix of steroids and immunosuppressants that can be effective but are often difficult to optimize in practice.

   The company’s commercial model complements the product profile. Rather than deploy a massive primary-care sales force, Aurinia uses a focused specialty-commercial approach, hub services, market-access support, and medical-affairs engagement to win a relatively small number of high-value prescribing relationships. Outside the U.S., the company plans to win through capital-efficient partnering. Beyond LUPKYNIS, it appears to favor selective business development and targeted pipeline expansion over trying to build a large discovery engine from scratch.

4. 1d. What capabilities must Aurinia have in place?

   To execute this strategy, Aurinia needs a handful of very specific capabilities:

   • Deep clinical and regulatory expertise in lupus nephritis, nephrology, and autoimmune disease.
   • A small but effective specialty-commercial engine that can influence a concentrated prescriber base.
   • Strong payer-access, reimbursement, and patient-support capabilities, because prior authorization and affordability materially affect treatment starts.
   • Reliable outsourced manufacturing, quality, and pharmacovigilance systems for a commercial drug.
   • Business-development and portfolio-selection discipline so new pipeline investments fit the company’s scale and balance sheet.
   • Partner-management capability for ex-U.S. collaborations.

5. 1e. What management systems does Aurinia require?

   Aurinia’s management systems need to be more precise than broad. In a single-product specialty-pharma company, the critical systems are the ones that track the patient funnel from diagnosis to prescription to fill to persistence. That means tight monitoring of prescription trends, gross-to-net deductions, payer wins and losses, inventory, safety reporting, and field-force productivity.

   It also needs disciplined portfolio governance. Because Aurinia does not have the scale of a large pharmaceutical company, management must continuously decide how much capital to allocate to LUPKYNIS growth, how much to invest in pipeline assets, and whether external business development creates more value than internal expansion. Cash management, board oversight, and clear development-stage gates are therefore central to strategy execution.

2. What Are the Current Strategic Initiatives of Aurinia?

As described in its 2023 annual reporting and 2024 investor communications, Aurinia’s agenda is focused and practical rather than expansive. The company’s main initiatives appear to be the following:

• Expand U.S. LUPKYNIS adoption in lupus nephritis. Aurinia continues to focus on growing new patient starts, increasing prescribing breadth among nephrologists and rheumatologists, and improving the conversion of diagnosed patients into treated patients. For Aurinia, growth is not mainly about adding many products; it is about deeper penetration of a defined disease state.
• Improve access, initiation, and persistence. In specialty pharma, the prescription is only part of the sale. Aurinia has continued to emphasize reimbursement support, specialty-pharmacy coordination, and patient-services infrastructure because therapy starts can stall on prior authorizations, affordability, or onboarding friction.
• Reinforce the clinical case for LUPKYNIS. Medical-affairs work, long-term follow-up from the AURORA clinical program, publications, congress activity, and real-world evidence all support the same objective: make physicians more comfortable using LUPKYNIS as part of routine lupus-nephritis care.
• Monetize ex-U.S. territories through partners. Rather than build its own global commercial network, Aurinia has used partnership structures, including Otsuka in certain ex-U.S. territories, to extend geographic reach while controlling cost.
• Broaden the autoimmune pipeline. Public disclosures in 2023 and 2024 indicate that Aurinia is trying to evolve from a one-product story into a broader autoimmune company. The lead disclosed non-LUPKYNIS pipeline asset is AUR200, and the broader strategic goal is to add future growth drivers beyond voclosporin.
• Maintain capital discipline. Aurinia’s strategic posture has also included careful allocation of cash between commercial support, pipeline investment, and broader capital-allocation choices. That discipline matters because the company has meaningful resources for its size, but it still lacks the diversification of a larger pharma company.

3. What Is the Business Model of Aurinia?

What customers actually buy

Aurinia’s current business model is straightforward: customers buy access to LUPKYNIS, a branded prescription therapy for adults with active lupus nephritis. The prescribing decision is made by specialists, the drug is reimbursed by payers, and distribution typically runs through specialty channels rather than broad retail pharmacy shelves. In some international markets, what counterparties buy from Aurinia is not the product itself but licensed rights, regulatory support, and ongoing collaboration economics.

Recurring versus one-time revenue

The core revenue stream is repeat-driven. Lupus nephritis is not a one-visit condition, so patients who start and remain on therapy can generate recurring prescription revenue. That makes persistence and refill behavior important. By contrast, partnership-related revenue such as upfront payments, milestones, or certain collaboration payments is episodic and less predictable.

How the revenue model works

Aurinia’s revenue model is that of a specialty pharmaceutical company: branded drug sales in its direct markets, plus collaboration and royalty economics in partnered territories. It is not subscription-based, usage-metered, or equipment-driven. Revenue rises primarily through more patients on therapy, better access, higher refill continuity, and, to a lesser extent, favorable mix in gross-to-net deductions.

How pricing power works

Aurinia has some pricing power because LUPKYNIS is a branded therapy in a serious disease with limited branded competition. But that power is constrained. Net realized pricing is shaped by payer negotiations, rebates, co-pay assistance, and the practical need to reduce access barriers in a relatively small specialty market. In other words, list price matters less than successful reimbursement and patient pull-through.

Why the business mix matters

The business mix matters because Aurinia is still heavily concentrated around one product. That gives the company a relatively clean investment story, but it also means any change in LUPKYNIS growth, reimbursement, safety perception, or competitive intensity can have an outsized effect on revenue and valuation.

What drives margins and cash generation

Gross margin should be structurally attractive because LUPKYNIS is a branded oral drug and Aurinia operates with an outsourced manufacturing model rather than a large owned plant network. Operating margin, however, is shaped by fixed commercial costs, medical affairs, patient-support infrastructure, and pipeline spending. Cash generation depends on continued prescription growth and disciplined operating expense, while capital expenditure requirements are modest relative to asset-heavy industries.

4. What Products and/or Services Does Aurinia Sell?

Aurinia’s commercial portfolio is unusually concentrated.

• LUPKYNIS (voclosporin). This is the company’s flagship and overwhelmingly most important product. It is an oral calcineurin inhibitor approved in the U.S. for adults with active lupus nephritis. It drives the company’s current product revenue and defines most of the organization’s commercial priorities.
• Ex-U.S. licensing and collaboration economics. Aurinia also derives value from partnership arrangements in territories where it has chosen not to build a full direct commercial presence. These arrangements can include upfronts, milestones, royalties, and other collaboration income.
• Pipeline programs. Aurinia has disclosed early-stage autoimmune pipeline efforts, led publicly by AUR200. These are strategically important because they represent the company’s attempt to build a second growth leg, but they do not yet contribute meaningful commercial revenue.

There is no large legacy portfolio to manage. In practical terms, Aurinia is a one-product specialty pharma company with an emerging pipeline behind it.

5. What Are the Key Competitors or Peers of Aurinia?

Direct branded competition in lupus nephritis is limited, so it is more accurate to think of Aurinia’s competitive set as a mix of direct rivals, therapeutic substitutes, and nephrology-focused specialty-pharma peers.

6. What Is the Marketing Strategy of Aurinia?

Aurinia’s marketing strategy is typical of a focused specialty-pharma company, but with an extra emphasis on disease-state complexity. Lupus nephritis sits between nephrology and rheumatology, so marketing is as much about education and pathway management as it is about brand promotion.

• Specialist-focused promotion. Aurinia markets primarily to a concentrated universe of nephrologists and rheumatologists rather than to broad primary-care audiences.
• Medical education and scientific exchange. Publications, congress presence, key opinion leader engagement, and medical-affairs support are important because treatment adoption depends on physician confidence in the evidence base.
• Access and patient support as part of the commercial message. In this category, “marketing” extends beyond awareness. Reimbursement support, specialty-pharmacy coordination, and patient assistance materially affect whether a prescription becomes a filled, sustained therapy.
• Brand marketing is supportive, not dominant. Aurinia does not appear to compete through mass consumer advertising in the way some larger pharmaceutical brands do. The real differentiators are clinical profile, specialist education, and operational support around access.

In that sense, Aurinia’s marketing model is closer to account-based medical commercialization than to broad consumer brand building.

7. What Are the Key Customer Segments of Aurinia?

Aurinia’s effective customer base includes clinical decision-makers, economic gatekeepers, patients, and channel partners.

• Nephrologists. These specialists are central because lupus nephritis directly affects kidney function and often requires sustained renal monitoring.
• Rheumatologists. Many lupus nephritis patients are diagnosed and co-managed in rheumatology settings, so rheumatologists are a critical source of prescribing and referral activity.
• Adult patients with active lupus nephritis. The end patient population is relatively narrow compared with mass-market pharmaceuticals, which increases the importance of precise targeting and support.
• Payers, pharmacy benefit managers, and government programs. These are essential economic stakeholders because reimbursement, prior authorization, and co-pay structures influence access and persistence.
• Specialty pharmacies and specialty distributors. These channel partners handle fulfillment and can affect patient experience, data flow, and adherence support.
• Ex-U.S. commercial partners. In partnered markets, counterparties such as regional licensees become important customers in an economic sense because they generate milestones, royalties, and commercialization leverage.

Aurinia is therefore not diversified across many end markets. It is concentrated in one disease area, one core specialist ecosystem, and one main product.

8. What Is the Sales Model of Aurinia?

Aurinia uses a direct U.S. specialty-sales model for LUPKYNIS and a partner-led model outside the U.S.

In the United States, the company promotes to targeted nephrologists and rheumatologists through a focused field organization rather than a mass-detail model. Prescriptions flow through specialty distribution and specialty pharmacies, with reimbursement and patient-support programs helping address prior authorization, affordability, onboarding, and refill continuity. That channel structure gives Aurinia high visibility into patient starts and access friction, but it also means operational details matter: a clinically interested prescriber still may not produce revenue if the access process is slow or difficult.

Outside the U.S., Aurinia has generally chosen to sell through partners instead of building a costly in-house global infrastructure. That decision supports capital efficiency and reduces fixed overhead, but it also gives Aurinia less direct control over commercial execution in those markets.

The channel structure affects growth in an important way: success depends less on broad reach and more on precise specialist coverage, payer execution, and patient pull-through.

9. In What Geographies Does Aurinia Operate?

Aurinia’s commercial center of gravity is the United States. That is where LUPKYNIS is sold directly, where the main specialist field effort is focused, and where most near-term commercial execution matters.

The company is headquartered in Edmonton, Alberta, Canada, and it has maintained a meaningful operational presence in the United States, including commercial and medical-affairs functions in Maryland. Its physical footprint is relatively light because it does not operate a large owned manufacturing network; pharmaceutical production is outsourced.

Outside the U.S., Aurinia’s reach is broader in an economic sense than in an owned-infrastructure sense. The company has partnered certain territories outside the U.S., including parts of Europe and Japan through Otsuka, which allows it to participate in international opportunities without building a large standalone overseas sales and regulatory organization.

So Aurinia is geographically diversified by opportunity, but still quite concentrated operationally: Canada for corporate headquarters, the U.S. for direct commercialization, and partners for much of the rest of the world.

10. Who Are the Owners of Aurinia?

Aurinia is a publicly traded company. As of 2024, it did not publicly disclose a controlling shareholder. Ownership appeared to be primarily institutional, which is typical for a commercial-stage biotechnology company listed in public markets. In practical terms, Aurinia is manager-run rather than founder-controlled or family-controlled.

11. How Is Aurinia Organized?

Officially, Aurinia has reported one reportable segment, which is common for a company with a concentrated commercial portfolio. Practically, however, the organization can be understood in four operating layers:

• U.S. commercial operations focused on LUPKYNIS sales, market access, patient services, and field execution.
• Medical affairs, regulatory, and pharmacovigilance supporting a marketed autoimmune therapy and maintaining the evidence base around it.
• Research and development focused on pipeline expansion and lifecycle work.
• Corporate and partner-management functions covering finance, legal, business development, and ex-U.S. collaboration oversight.

This is not a diversified portfolio company with many autonomous business units. It is a focused specialty-pharma organization structured around one commercial asset and a relatively small set of growth options behind it.

12. How Does Aurinia Operate?

On a day-to-day basis, Aurinia operates more like an outsourced specialty-pharma platform than a vertically integrated drug manufacturer.

1. Drug supply is sourced through third parties. Aurinia relies on contract manufacturers and related vendors for active pharmaceutical ingredient production, finished dosage manufacturing, packaging, and related quality activities.
2. The company forecasts demand and manages inventory tightly. Because LUPKYNIS is the main revenue source, supply interruptions or inventory missteps matter disproportionately.
3. Commercial teams promote to specialist prescribers. Sales representatives, market-access personnel, and medical-affairs teams support prescribing behavior in nephrology and rheumatology.
4. Patient support infrastructure helps convert prescriptions into therapy starts. Hub services, reimbursement support, and specialty-pharmacy coordination are part of the operating engine, not just a peripheral service.
5. Regulatory and safety systems run continuously. As a commercial drug company, Aurinia must maintain pharmacovigilance, quality oversight, labeling compliance, and ongoing post-approval obligations.
6. Management also runs a parallel pipeline machine. That includes evaluating external opportunities, advancing disclosed pipeline assets, and deciding where limited development dollars can create the most strategic value.

The operational bottlenecks are therefore less about factory throughput and more about physician adoption, access friction, patient persistence, and disciplined outsourcing.

13. What Are the Growth Opportunities for Aurinia?

Aurinia’s most plausible growth opportunities are visible, but they are also constrained by concentration.

• Deeper penetration of diagnosed lupus nephritis patients. The clearest opportunity is simply getting more appropriate U.S. patients onto LUPKYNIS. Better diagnosis, faster referral, and more consistent use by nephrologists and rheumatologists can still expand the treated base.
• Improved patient conversion and persistence. Because revenue is repeat-driven, operational gains in prior authorization, affordability, onboarding, and refill continuity can matter almost as much as top-of-funnel awareness.
• International economics through partners. If ex-U.S. partners advance regulatory and commercial execution effectively, Aurinia can add royalties and milestones without taking on a large fixed-cost footprint.
• Pipeline diversification. The strategic upside from AUR200 and other autoimmune pipeline efforts is significant because any successful second asset would reduce dependence on LUPKYNIS.
• Selective business development. Aurinia has enough commercial and autoimmune expertise to be a plausible buyer or licensee of adjacent assets that fit its specialist model.

The main constraints are equally clear: one-product concentration, a finite addressable patient population, payer friction, physician conservatism in specialty treatment patterns, and future competition from both branded and pipeline therapies.

14. What Is the History of Aurinia?

• 1990s roots. Aurinia’s history traces back to Isotechnika, an Edmonton-based biotechnology company founded in 1993 and involved in the development of voclosporin.
• 2013 formation of the current company. Isotechnika merged with the privately held Aurinia business and adopted the Aurinia name, creating the current corporate identity.
• Clinical de-risking. Over the following years, voclosporin became the company’s defining asset, with clinical development in lupus nephritis moving from proof-of-concept toward registrational studies.
• 2017 phase 2 progress. Positive results from the AURA-LV study materially increased investor and industry attention on voclosporin in lupus nephritis.
• 2019 phase 3 validation. The AURORA program helped establish the efficacy profile needed for regulatory progress.
• 2020 ex-U.S. partnership. Aurinia entered a collaboration with Otsuka for certain territories outside the United States, consistent with its partner-led international strategy.
• 2021 commercial inflection point. The U.S. Food and Drug Administration approved LUPKYNIS in January 2021 for adults with active lupus nephritis, and Aurinia launched as a commercial-stage company.
• 2023-2024 transition toward a broader autoimmune story. With LUPKYNIS established as the revenue engine, Aurinia increasingly emphasized pipeline expansion and capital allocation alongside commercial execution.

15. What Are the Key Suppliers to Aurinia?

Suppliers matter a great deal to Aurinia because it is a commercial pharmaceutical company with a largely outsourced operating model.

The most important supplier categories are:

• Active pharmaceutical ingredient and finished-dose manufacturers that make LUPKYNIS and its components.
• Packaging and quality-release partners that support compliant commercial supply.
• Specialty distribution and pharmacy partners that move product to patients and generate operational data.
• Clinical research organizations and development vendors that support pipeline studies and lifecycle evidence generation.
• Regulatory, pharmacovigilance, and technology service providers that help maintain the infrastructure of a commercial biopharma business.

Like many smaller pharmaceutical companies, Aurinia has disclosed dependence on third parties and, in some cases, limited-source arrangements. That supplier structure matters strategically because disruption at a contract manufacturer or specialty channel partner can have an outsized effect when one product accounts for most of the company’s economics.

16. What Are the Key Brands Owned by Aurinia?

Aurinia’s brand architecture is simple.

• LUPKYNIS. This is the central commercial brand and by far the most important one. In Aurinia’s case, the brand is not just a name; it represents the company’s clinical evidence, specialist positioning, and payer-access strategy in lupus nephritis.
• Aurinia Alliance. Aurinia has used this patient-support identity in connection with access, reimbursement, and onboarding support. It is strategically important because patient-services infrastructure can materially influence starts and persistence.

Branding does matter, but not in the consumer-goods sense. In Aurinia’s market, clinical data, physician confidence, and reimbursement execution are more important than broad emotional brand advertising.

17. How Does the Supply Chain of Aurinia Function?

Aurinia’s supply chain is important, but it is not built around a large owned factory network. It is an outsourced pharmaceutical supply chain designed to support one high-value specialty medicine.

At a high level, the flow looks like this:

1. Source active pharmaceutical ingredient and other key inputs through qualified third-party suppliers.
2. Use contract manufacturers for finished product manufacturing and packaging.
3. Manage quality assurance, release, and regulatory compliance before commercial distribution.
4. Ship through specialty distribution channels and specialty pharmacies rather than broad retail networks.
5. Coordinate reimbursement support, patient onboarding, and refill logistics alongside the physical product flow.

Because LUPKYNIS is an oral small-molecule drug, Aurinia’s supply chain is simpler than the cold-chain logistics often required for biologics. Even so, reliability remains strategically important. A supply interruption would affect revenue immediately, and excess inventory or poor forecasting could pressure cash in a company with a relatively concentrated product base.

18. What Is the R&D Strategy of Aurinia?

Aurinia’s R&D strategy appears focused rather than platform-scale. The company is not trying to compete with large pharma on the breadth of discovery; it is trying to use its autoimmune and renal-disease expertise selectively.

• Lifecycle evidence for LUPKYNIS. Even after approval, Aurinia still needs to support the product with long-term data, real-world evidence, medical publications, and other work that reinforces physician confidence.
• Pipeline diversification. Public disclosures in 2023 and 2024 indicate that AUR200 is the lead disclosed asset behind LUPKYNIS. The larger strategic objective is to build follow-on growth options in autoimmune disease.
• Externalized development model. Aurinia’s R&D model appears to rely materially on external vendors, clinical research organizations, and business-development sourcing rather than a massive in-house discovery engine. That is a rational choice for a company of its size.
• Portfolio selectivity. Aurinia’s R&D success will likely depend less on the number of programs it touches and more on choosing assets that fit its commercial scale, scientific expertise, and financial capacity.

An important inference from Aurinia’s public strategy is that R&D is meant to reduce concentration risk, not just add scientific optionality.

19. What Is the Finance Strategy of Aurinia?

Aurinia’s finance strategy is shaped by an unusual combination: it has meaningful commercial revenue and a comparatively strong balance-sheet position for its size, but it is still concentrated around one marketed product.

That creates a capital-allocation agenda with four parts:

• Fund LUPKYNIS commercialization efficiently. The first priority is supporting the existing revenue engine without letting selling costs outrun the addressable market.
• Preserve balance-sheet flexibility. Aurinia has historically emphasized liquidity and optionality, which is important in a sector where pipeline setbacks or access pressure can change outlook quickly.
• Invest selectively in pipeline and business development. The company’s financial strategy supports a transition from a single-product company toward a broader autoimmune portfolio, but likely with a preference for measured rather than aggressive dealmaking.
• Manage shareholder returns versus reinvestment. For a company at Aurinia’s stage, the core finance question is whether excess capital should support internal growth, external assets, or return mechanisms such as repurchases when available.

The broader point is that finance at Aurinia is not mainly about repairing a balance sheet. It is about disciplined deployment of capital in a business where concentration risk remains high.

20. How Companies Like Aurinia Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Aurinia use Umbrex when they need that caliber of problem solving without hiring a full consulting team and its associated overhead. Umbrex consultants work across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI, which fits well with the needs of a focused specialty-biopharma company balancing one commercial franchise with pipeline expansion.

• Lupus-nephritis market segmentation and prescriber prioritization. Re-map the U.S. opportunity by account, specialty, referral pattern, and patient funnel leakage.
• Rheumatology-nephrology referral pathway redesign. Identify where co-management breaks down and build interventions that improve diagnosis-to-treatment conversion.
• Patient-services and reimbursement optimization. Redesign hub operations, prior-authorization workflows, and affordability support to improve therapy starts and persistence.
• Field-force sizing and territory alignment. Optimize specialist coverage, call plans, and resource deployment for a narrow prescriber universe.
• Gross-to-net and payer-access review. Analyze contracting, payer mix, channel deductions, and access barriers to improve net revenue quality.
• Ex-U.S. partner strategy assessment. Evaluate whether current partner structures are delivering adequate value and where Aurinia should deepen, renegotiate, or expand territory coverage.
• Pipeline portfolio prioritization. Build a stage-gated framework to compare AUR200 and other autoimmune opportunities against internal return thresholds and strategic fit.
• Business-development target scan. Screen external autoimmune and renal-disease assets that could fit Aurinia’s commercial model without overextending the balance sheet.
• CMO and supply-chain resilience program. Review single-source risk, inventory strategy, quality governance, and contingency planning for LUPKYNIS supply.
• Commercial analytics and AI-enabled decision support. Build dashboards and predictive models for starts, refills, access friction, and field-force effectiveness so management can allocate resources faster.